Nonnutritive Sweeteners and Cardiovascular Risk Authors: Karl Nadolsky Published: 2026 ABSTRACT Graphical Abstract I read with enthusiasm the recent state-of-the-art review by Miller et al1 on trending cardiovascular nutritional controversies in 2026. While I commend the authors for addressing clinically relevant dietary topics, this author respectfully contends that the classification of artificial sweeteners, or nonnutritive sweeteners (NNSs), under “evidence of harm” misrepresents the totality of available clinically applicable evidence by over-relying on observational associations while omitting a robust body of interventional trial data demonstrating cardiometabolic safety and benefit (Figure 1). Observational Data Raise Concerns, But Interventional Trial Data Reassure Cardiometabolic Safety of Nonnutritive Sweeteners Observational data have consistently raised the concern about NNS/ASB correlating to obesity, cardiometabolic risk, and cardiovascular events. To the contrary, interventional trials consistently show superiority of NNS/ASB over sugar-sweetened beverages, some even equivalent or superior to water. Additionally, some of best quality nutritional research shows clinical benefit of including meal replacements flavored using NNS for weight loss, type 2 diabetes prevention or remission and all cardiometabolic risk factors accompanied by safety reassurance. ASB = artificially sweetened beverage; ASCVD = atherosclerotic cardiovascular disease; NNS = nonnutritive sweetener; ORD = obesity-related disease; T2D = type 2 diabetes; SSB = sugar-sweetened beverages. The authors cite large prospective cohort studies associating artificially sweetened beverage (ASB) consumption with increased cardiovascular disease risk. However, as has been extensively discussed in the literature, observational nutrition data are inherently limited by reverse causation, surveillance bias, and residual confounding. Individuals consuming ASBs often do so because of pre-existing cardiometabolic disease, a well-recognized methodological pitfall that inflates apparent risk. Correlation does not imply causation, and hypothesis-generating observational findings should not supplant a plethora of better-quality interventional evidence when guiding clinical recommendations. A recent systematic review and meta-analysis by Qin et al2 of randomized controlled trials found that NNSs do not adversely influence metabolic risk factors, including glucose, insulin, lipids, or blood pressure. Regarding postprandial glycemia, specifically, a systematic review and network meta-analysis by Zhang et al3 demonstrated no detrimental glycemic or endocrine effects of NNS-containing beverages. Furthermore, multiple meta-analyses of randomized controlled trials, including those cited by the authors themselves, consistently show that substituting NNSs for sugar-sweetened beverages produces modest but significant reductions in body weight, body mass index, fat mass, and waist circumference.1 These are not trivial endpoints: adiposity is among the most potent modifiable drivers of metabolic syndrome, type 2 diabetes, and cardiovascular disease risk. Importantly, the authors omit a compelling body of indirect interventional evidence from meal replacement research. NNS-sweetened protein shakes have been the cornerstone of structured very-low-energy dietary programs including DiRECT, PREVIEW, Look AHEAD, and DROPLET; programs that have demonstrated substantial weight loss, type 2 diabetes remission, and cardiometabolic improvement without evidence of harm attributable to NNS content. A recent systematic review and meta-analysis by Noronha et al4 of randomized controlled trials using meal replacements in individuals with prediabetes and metabolic syndrome confirmed significant reductions in weight, waist circumference, fasting glucose, triglycerides, and blood pressure. Dismissing NNSs as harmful implicitly calls into question these evidence-based therapeutic strategies. I agree that unsweetened water, tea, and coffee are preferable default beverages despite some trials showing equivalence or superiority of ASB.5 While NNSs are not universally appropriate or necessary for patients consuming sugar-sweetened beverages who are unwilling or unable to transition to unsweetened alternatives, NNS-sweetened beverages represent a pragmatically superior option. Classifying NNSs alongside beef tallow and ultra-processed foods as agents of harm without adequately acknowledging the causality limitations of observational data or the breadth of favorable interventional evidence risks undermining clinically beneficial dietary substitutions. I encourage the authors to consider a more nuanced interpretation in future guidance. Footnotes The author has reported that they have no relationships relevant to the contents of this paper to disclose. The author attests they are in compliance with human studies committees and animal welfare regulations of the author’s institution and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References